ASCO 2024 Breast Cancer

CME

Key Studies in Breast Cancer: Independent Conference Coverage of the 2024 ASCO Annual Meeting

Physicians: Maximum of 0.75 AMA PRA Category 1 Credit

Released: August 14, 2024

Expiration: February 13, 2025

Sara A. Hurvitz
Sara A. Hurvitz, MD, FACP
Kevin Kalinsky
Kevin Kalinsky, MD, MS

Activity

Progress
1 2
Course Completed

References

  1. Curigliano G, Hu X, Dent RA, et al. Trastuzumab deruxtecan (T-DXd) vs physician’s choice of chemotherapy (TPC) in patients (pts) with hormone receptor-positive (HR+), human epidermal growth factor receptor 2 (HER2)-low or HER2-ultralow metastatic breast cancer (mBC) with prior endocrine therapy (ET): Primary results from DESTINY-Breast06 (DB-06). Presented at: American Society of Clinical Oncology; May 31-June 4, 2024. Abstr LBA1000.
  2. Modi S, Jacot W, Yamashita T, et al. Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer. N Engl J Med. 2022;387:9-20.
  3. Kalinsky K, Accordino MK, Chiuzan C, et al. Randomized phase II trial of endocrine therapy with or without ribociclib after progression on cyclin-dependent kinase 4/6 inhibition in hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer: MAINTAIN Trial. J Clin Oncol. 2023;41:4004-4013.
  4. Mayer EL, Ren Y, Wagle N, et al. PACE: A randomized phase II study of fulvestrant, palbociclib, and avelumab after progression on cyclin-dependent kinase 4/6 inhibitor and aromatase inhibitor for hormone receptor-positive/human epidermal growth factor receptor-negative metastatic breast cancer. J Clin Oncol. 2024;42:2050-2060.
  5. Kalinsky K, Bianchini G, Hamilton EP, et al. Abemaciclib plus fulvestrant vs fulvestrant alone for HR+, HER2- advanced breast cancer following progression on a prior CDK4/6 inhibitor plus endocrine therapy: Primary outcome of the phase 3 postMONARCH trial. Presented at: American Society of Clinical Oncology; May 31-June 4, 2024. Abstr LBA1001.
  6. Garrido-Castro AC, Kim SE, J D, et al. A randomized phase II trial of sacituzumab govitecan with or without pembrolizumab in patients with metastatic hormone receptor-positive/HER2-negative breast cancer. Presented at: American Society of Clinical Oncology; May 31-June 4, 2024. Abstr LBA1004.
  7. Loi S, Curigliano G, Salgado RF, al e. A randomized, double-blind trial of nivolumab (NIVO) vs placebo (PBO) with neoadjuvant chemotherapy (NACT) followed by adjuvant endocrine therapy (ET) ± NIVO in patients (pts) with high-risk, ER+ HER2− primary breast cancer (BC). Presented at: European Society of Medical Oncology Congress; October 20-24, 2023. Abstr LBA20.
  8. Cardoso F, McArthur HL, Schmid P, et al. Phase III study of neoadjuvant pembrolizumab (pembro) or placebo (pbo) + chemotherapy (chemo), followed by adjuvant pembro or pbo + endocrine therapy (ET) for early-stage high-risk ER+/HER2– breast cancer. Presented at: European Society of Medical Oncology Congress; October 20-24, 2023. Abstr LBA21.
  9. Andre F, Hamilton EP, Loi S, et al. DESTINY-Breast07: Dose-expansion interim analysis of T-DXd monotherapy and T-DXd + pertuzumab in patients with previously untreated HER2+ mBC. Presented at: American Society of Clinical Oncology May 31-June 4, 2024. Abstr 1009.
  10. Swain SM, Baselga J, Kim SB, et al. Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer. N Engl J Med. 2015;372:724-734.
  11. Bardia A, Jhaveri K, Im S-A, et al. Datopotamab deruxtecan (Dato-DXd) vs chemotherapy in previously-treated inoperable or metastatic hormone receptor-positive, HER2-negative (HR+/HER2–) breast cancer (BC): Primary results from the randomised phase III TROPION-Breast01 trial. Presented at: European Society of Medical Oncology Congress; October 20-24, 2023. Abstr LBA11.
  12. Shatsky RA, Trivedi MS, Omene CO, et al. Rates of pathologic complete response (pCR) after datopotamab deruxtecan (Dato) plus durvalumab (Durva) in the neoadjuvant setting: Results from the I-SPY2.2 trial. Presented at: American Society of Clinical Oncology; May 31-June 4, 2024. Abstr LBA501.
  13. Meisel JL, Khoury K, Chien AJ, et al. Rates of pathologic complete response (pCR) after neoadjuvant datopotamab deruxtecan (Dato): Results from the I-SPY2.2 trial. Presented at: Amelrican Society of Clinical Oncology; May 31-June 4, 2024. Abstr LBA509.
  14. Wolf DM, Yau C, Wulfkuhle J, et al. Redefining breast cancer subtypes to guide treatment prioritization and maximize response: Predictive biomarkers across 10 cancer therapies. Cancer Cell. 2022;40:609-623 e606.
  15. Conte PF, Dieci MV, Bisagni G, et al. A-BRAVE trial: A phase III randomized trial with avelumab in early triple-negative breast cancer with residual disease after neoadjuvant chemotherapy or at high risk after primary surgery and adjuvant chemotherapy. Presented at: American Society of Clinical Oncology; May 31-June 4, 2024. Abstr LBA500.
  16. McArthur H, Bailey A, Sajl S, et al. Adjuvant chemotherapy with or without atezolizumab for stage II and III triple-negative breast cancer: final analysis of the ALEXANDRA/Impassion030 phase 3 trial. Presented at: European Breast Cancer Conference March 20-22, 2024. Abstr LBA1.
  17. Patel SP, Othus M, Chen Y, et al. Neoadjuvant-adjuvant or adjuvant-only pembrolizumab in advanced melanoma. N Engl J Med. 2023;388:813-823.
  18. Johnston SRD, Harbeck N, Hegg R, et al. Abemaciclib combined with endocrine therapy for the adjuvant treatment of HR+, HER2-, node-positive, high-risk, early breast cancer (monarchE). J Clin Oncol. 2020;38:3987-3998.
  19. Slamon D, Lipatov O, Nowecki Z, et al. Ribociclib plus endocrine therapy in early breast cancer. N Engl J Med. 2024;390:1080-1091.
  20. Yardley DA, Untch M, Barrios CH, et al. Baseline (BL) characteristics and efficacy endpoints for patients (pts) with node-negative (N0) HR+/HER2− early breast cancer (EBC): NATALEE trial. Presented at: American Society of Clinical Oncology May 31-June 4, 2024. Abstr 512.
  21. Kalinsky K, Barlow WE, Gralow JR, et al. 21-Gene assay to inform chemotherapy benefit in node-positive breast cancer. N Engl J Med. 2021;385:2336-2347.
  22. Kalinsky K, Barlow WE, Pathak HB, et al. Correlation of serum anti-Müllerian hormone (AMH) levels on identification of premenopausal patients (pts) with hormone receptor positive (HR+), HER2-negative, node-positive breast cancer most likely to benefit from adjuvant chemotherapy in SWOG S1007 (RxPONDER). Presented at: American Society of Clinical Oncology; May 31-June 4, 2024. Abstr 512.